Concord Drugs Ltd (BSE: 538965) is a Hyderabad, Telangana-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹96 Cr, it ranks #3,274 by market cap among the 6,197 Indian listed companies on FinBizNet, and #17 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹73.54 (as of 16 Nov 2026), the share price is 19.9% below its 52-week high of ₹91.79 and 22.6% above its 52-week low of ₹59.99. The share price is down 3.4% over one year and up 1.6% over three months.
| Current Price | ₹73.54 |
|---|---|
| Market Cap | ₹96 Cr |
| BSE Code | 538965 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 77.7 |
| Return on Equity | 2.55% |
| Return on Assets | 2.81% |
| 52-Week Range | ₹59.99 – ₹91.79 |
| 1-Year Price Change | -3.4% |
| 3-Month Price Change | +1.6% |
| Beta (1Y) | 0.48 |
| Headquarters | Hyderabad, Telangana |
| Website | concorddrugs.in |
Promoters held 51.43% of Concord Drugs Ltd's shares as of Mar 2026, against 51.39% in Mar 2025 (+0.04 percentage points). Delivery averaged 76.4% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Concord Drugs Limited engages in the manufacture and sale of pharmaceutical formulations in India. It offers tissue bio-adhesive products; ready-to-fill pellets and multiple unit pellets system; other drugs in the form of tablets, capsules, small volume parenterals, dry powders, syrups and suspension, and dry syrups; and hand sanitizers. The company was incorporated in 1995 and is based in Hyderabad, India.
1. Manufacture of Pharmaceutical Formulations-This segment manufactures and sells finished pharmaceutical formulations. 2. Segment Adjustment-0 3. Trading-This segment engages in trading of packing material.
1. Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Concord Drugs Ltd | ₹96 Cr | 77.7 | 2.55% | — | -3.4% |
Listed by market capitalisation. Ratios are shown for context only.
Concord Drugs Ltd is trading at ₹73.54, with a market capitalisation of ₹96 Cr.
Concord Drugs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Concord Drugs Ltd has a P/E of 77.7 and a return on equity of 2.55%.
Concord Drugs Ltd is listed on the BSE under the scrip code 538965.
Concord Drugs Ltd's share price is down 3.4% over one year and up 1.6% over three months. Its 52-week range is ₹59.99 to ₹91.79.
Promoters held 51.43% of Concord Drugs Ltd's shares as of Mar 2026, against 51.39% in Mar 2025 (+0.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.